CMPX Compass Therapeutics, Inc.
Healthcare$2.07+7.25%ClosedMarket Cap: $286.3M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.07
P/S
0.00
EV/EBITDA
-3.32
DCF Value
$0.12
FCF Yield
-18.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-39.7%
ROA
-33.2%
ROIC
-38.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-20.3M | $-18.3M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-18.0M | $-15.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-72.8M | $-66.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-15.8M | $-14.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-21.1M | $-19.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-18.0M | $-16.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-16.6M | $-15.0M | $— | — |
| FY null | $850.0K | 100.0% | $-56.6M | $-49.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-12.2M | $-10.5M | $— | — |
| Q2 null | $850.0K | 100.0% | $-15.0M | $-13.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-12.8M | $-10.8M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-15.4M | $-13.4M | $-0.11 | — |